{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T11:01:29Z","timestamp":1793185289266,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.semarthrit.2018.11.005","type":"journal-article","created":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T02:35:55Z","timestamp":1543890955000},"page":"74-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":148,"title":["Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature"],"prefix":"10.1016","volume":"49","author":[{"given":"Nina","family":"Kello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara El","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina","family":"Marder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Furie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterini","family":"Zapantis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane Lewis","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.semarthrit.2018.11.005_bib0001","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1111\/j.1538-7836.2005.01350.x","article-title":"Thrombotic thrombocytopenic purpura and its diagnosis","volume":"3","author":"Veyradier","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.semarthrit.2018.11.005_bib0002","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0049-0172(94)90073-6","article-title":"Systemic lupus erythematosus complicated by thrombotic microangiopathy","volume":"24","author":"Jain","year":"1994","journal-title":"Semin Arthritis Rheum"},{"issue":"17","key":"10.1016\/j.semarthrit.2018.11.005_bib0003","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.semarthrit.2018.11.005_bib0004","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.semarthrit.2018.11.005_bib0005","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMoa031688","article-title":"Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria","volume":"350","author":"Hillmen","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2018.11.005_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.05.007","article-title":"The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: a comprehensive review","volume":"92","author":"Cervera","year":"2018","journal-title":"J Autoimmun"},{"key":"10.1016\/j.semarthrit.2018.11.005_bib0007","first-page":"139","article-title":"KDIGO Clinical Practice Guideline for Glomerulonephritis","volume":"2","year":"2012","journal-title":"Kidney inter., Suppl."},{"issue":"18","key":"10.1016\/j.semarthrit.2018.11.005_bib0008","doi-asserted-by":"crossref","first-page":"e3595","DOI":"10.1097\/MD.0000000000003595","article-title":"Plasmapheresis is associated with better renal outcomes in lupus nephritis patients with thrombotic microangiopathy: a case series study","volume":"95","author":"Li","year":"2016","journal-title":"Med (Baltimore)"},{"issue":"21","key":"10.1016\/j.semarthrit.2018.11.005_bib0009","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMra1705454","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"378","author":"Garcia","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.semarthrit.2018.11.005_bib0010","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s10157-010-0300-5","article-title":"Rapidly progressive lupus nephritis and concomitant thrombotic microangiopathy","volume":"14","author":"Gharbi","year":"2010","journal-title":"Clin Exp Nephrol"},{"issue":"7","key":"10.1016\/j.semarthrit.2018.11.005_bib0011","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/rheumatology\/key082","article-title":"CAPS Registry Project Group; The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients","volume":"57","author":"Rodr\u00edguez-Pint\u00f3","year":"2018","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.semarthrit.2018.11.005_bib0012","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.clim.2013.02.014","article-title":"Targeting the complement system in systemic lupus erythematosus and other diseases","volume":"148","author":"Barilla-Labarca","year":"2013","journal-title":"Clin Immunol"},{"issue":"11","key":"10.1016\/j.semarthrit.2018.11.005_bib0013","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1002\/art.40219","article-title":"The Evolving landscape for complement therapeutics in rheumatic and autoimmune diseases","volume":"69","author":"Thurman","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.11.005_bib0014","first-page":"S35","article-title":"A single dose, placebocontrolled, double blind, phase I study of the humanized anti-C5 antibody h5G1.1 in patients with systemic lupus erythematosus","volume":"50","author":"Furie","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.semarthrit.2018.11.005_bib0015","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.semarthrit.2018.11.005_bib0016","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"7","key":"10.1016\/j.semarthrit.2018.11.005_bib0017","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1191\/0961203303lu394oa","article-title":"Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines","volume":"12","author":"Asherson","year":"2003","journal-title":"Lupus"},{"issue":"7","key":"10.1016\/j.semarthrit.2018.11.005_bib0018","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2018.11.005_bib0019","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2010050451","article-title":"The development of atypical hemolytic uremic syndrome depends on complement C5","volume":"22","author":"de Jorge","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.semarthrit.2018.11.005_bib0020","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1182\/blood-2005-10-007252","article-title":"Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome","volume":"108","author":"Caprioli","year":"2006","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.semarthrit.2018.11.005_bib0021","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s00467-012-2131-y","article-title":"Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics","volume":"27","author":"Geerdink","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.semarthrit.2018.11.005_bib0022","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fimmu.2016.00055","article-title":"Systemic lupus erythematosus and deficiencies of early components of the complement classical pathway","volume":"7","author":"Macedo","year":"2016","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.semarthrit.2018.11.005_bib0023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002079","article-title":"Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility","volume":"7","author":"Zhao","year":"2011","journal-title":"PLoS Genet"},{"issue":"16","key":"10.1016\/j.semarthrit.2018.11.005_bib0024","doi-asserted-by":"crossref","first-page":"8563","DOI":"10.1073\/pnas.93.16.8563","article-title":"Amelioration of lupus-like autoimmune disease in NZB\/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5","volume":"93","author":"Wang","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.semarthrit.2018.11.005_bib0025","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000431278","article-title":"Complement in lupus nephritis: new perspectives","volume":"1","author":"Bao","year":"2015","journal-title":"Kidney Dis (Basel)"},{"issue":"3","key":"10.1016\/j.semarthrit.2018.11.005_bib0026","first-page":"235","article-title":"Vascular lesions in lupus nephritis","volume":"1","author":"Grishman","year":"1988","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.semarthrit.2018.11.005_bib0027","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/oxfordjournals.ndt.a027822","article-title":"Renal thrombotic microangiopathy in systemic lupus erythematosus: clinical correlations and long-term renal survival","volume":"13","author":"Bridoux","year":"1998","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.semarthrit.2018.11.005_bib0028","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0046-8177(86)80293-3","article-title":"Lupus glomerulonephritis with thrombotic microangiopathy","volume":"17","author":"Magil","year":"1986","journal-title":"Hum Pathol"},{"issue":"4","key":"10.1016\/j.semarthrit.2018.11.005_bib0029","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1093\/rheumatology\/keq311","article-title":"Thrombotic microangiopathy in systemic lupus erythematosus: a cohort study in North Taiwan","volume":"50","author":"Chen","year":"2011","journal-title":"Rheumatol (Oxford)"},{"key":"10.1016\/j.semarthrit.2018.11.005_bib0030","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1136\/annrheumdis-2018-eular.6871","article-title":"FRI0302\u2005Systemic lupus erythematosus-associated thrombotic microangiopathies in 60 patients: clinical features, prognosis and treatment in a french multicentric cohort","volume":"77","author":"Couture","year":"2018","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"5","key":"10.1016\/j.semarthrit.2018.11.005_bib0031","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.ekir.2017.04.008","article-title":"Effect of thrombotic microangiopathy on clinical outcomes in indian patients with lupus nephritis","volume":"2","author":"Pattanashetti","year":"2017","journal-title":"Kidney Int Rep"},{"issue":"5","key":"10.1016\/j.semarthrit.2018.11.005_bib0032","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrneph.2014.38","article-title":"Renal involvement in antiphospholipid syndrome","volume":"10","author":"Sciascia","year":"2014","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"10.1016\/j.semarthrit.2018.11.005_bib0033","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar4142","article-title":"The spectrum of renal thrombotic microangiopathy in lupus nephritis","volume":"15","author":"Song","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.semarthrit.2018.11.005_bib0034","first-page":"503","article-title":"Thrombotic microangiopathy and poor renal outcome in lupus patients with or without antiphospholipid syndrome","volume":"33","author":"Hernandez-Molina","year":"2015","journal-title":"Clin Exp Rheumatol"},{"issue":"14","key":"10.1016\/j.semarthrit.2018.11.005_bib0035","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1177\/0961203310376523","article-title":"Clinical characteristics and prognosis of diffuse proliferative lupus nephritis with thrombotic microangiopathy","volume":"19","author":"Hu","year":"2010","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.semarthrit.2018.11.005_bib0036","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00467-014-2944-y","article-title":"Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy","volume":"30","author":"Coppo","year":"2015","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"10.1016\/j.semarthrit.2018.11.005_bib0037","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1053\/j.ajkd.2014.07.031","article-title":"Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab","volume":"65","author":"El-Husseini","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2018.11.005_bib0038","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1136\/ard.2003.007245","article-title":"Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies","volume":"63","author":"Espinosa","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2018.11.005_bib0039","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.semarthrit.2007.08.001","article-title":"Relapsing catastrophic antiphospholipid syndrome: report of three cases","volume":"37","author":"Asherson","year":"2008","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.semarthrit.2018.11.005_bib0040","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.semarthrit.2012.05.005","article-title":"Antibodies CASCRPGEFoA. Relapsing catastrophic antiphospholipid syndrome potential role of microangiopathic hemolytic anemia in disease relapses","volume":"42","author":"Espinosa","year":"2013","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2018.11.005_bib0041","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1136\/ard.2008.090670","article-title":"Complement activation in patients with primary antiphospholipid syndrome","volume":"68","author":"Oku","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.semarthrit.2018.11.005_bib0042","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1172\/JCI200318817","article-title":"Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome","volume":"112","author":"Girardi","year":"2003","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.semarthrit.2018.11.005_bib0043","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1191\/0961203303lu397oa","article-title":"Activation of complement mediates antiphospholipid antibody-induced pregnancy loss","volume":"12","author":"Salmon","year":"2003","journal-title":"Lupus"},{"issue":"5","key":"10.1016\/j.semarthrit.2018.11.005_bib0044","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.semarthrit.2018.11.005_bib0045","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000492033","article-title":"When to stop eculizumab in complement-mediated thrombotic microangiopathies","volume":"48","author":"Olson","year":"2018","journal-title":"Am J Nephrol"},{"issue":"3","key":"10.1016\/j.semarthrit.2018.11.005_bib0046","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.seminhematol.2018.04.009","article-title":"Anticomplement treatment in atypical and typical hemolytic uremic syndrome","volume":"55","author":"Fakhouri","year":"2018","journal-title":"Semin Hematol"},{"key":"10.1016\/j.semarthrit.2018.11.005_bib0047","unstructured":"Jan Menne, Yahsou Delmas, Fadi Fakhouri, John F. Kincaid, Christoph Licht, Enrico E. Minetti, Chris Mix, Fran\u00e7ois Prov\u00f4t, Eric Rondeau, Neil S. Sheerin, Jimmy Wang, Laurent E. Weekers, Larry A. Greenbaum; Eculizumab prevents thrombotic microangiopathy in patients with atypical haemolytic uraemic syndrome in a long-term observational study, Clinical Kidney Journal, sfy035."},{"issue":"3","key":"10.1016\/j.semarthrit.2018.11.005_bib0048","first-page":"310","article-title":"Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome","volume":"10","author":"Macia","year":"2017","journal-title":"Clin Kidney J"},{"issue":"3","key":"10.1016\/j.semarthrit.2018.11.005_bib0049","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/blood-2017-02-770214","article-title":"Eculizumab cessation in atypical hemolytic uremic syndrome","volume":"130","author":"Merrill","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semarthrit.2018.11.005_bib0050","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.molimm.2015.03.246","article-title":"Atypical aHUS: state of the art","volume":"67","author":"Nester","year":"2015","journal-title":"Mol Immunol"},{"issue":"11","key":"10.1016\/j.semarthrit.2018.11.005_bib0051","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2169\/internalmedicine.0228-17","article-title":"A rare case of lupus nephritis presenting as thrombotic microangiopathy with diffuse pseudotubulization possibly caused by atypical hemolytic uremic syndrome","volume":"57","author":"Ono","year":"2018","journal-title":"Intern Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2018.11.005_bib0052","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.transci.2017.02.007","article-title":"Complement inhibition with eculizumab for thrombotic microangiopathy rescues a living-donor kidney transplant in a patient with antiphospholipid antibody syndrome","volume":"56","author":"Geethakumari","year":"2017","journal-title":"Transfus Apher Sci"},{"issue":"12","key":"10.1016\/j.semarthrit.2018.11.005_bib0053","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1007\/s10067-017-3823-2","article-title":"Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review","volume":"36","author":"de Holanda","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2018.11.005_bib0054","doi-asserted-by":"crossref","first-page":"e6338","DOI":"10.1097\/MD.0000000000006338","article-title":"Effect on mother and child of eculizumab given before caesarean section in a patient with severe antiphospholipid syndrome: a case report","volume":"96","author":"Gustavsen","year":"2017","journal-title":"Med. (Baltimore)"},{"issue":"16","key":"10.1016\/j.semarthrit.2018.11.005_bib0055","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1182\/bloodadvances.2018019596","article-title":"Complement-mediated thrombotic microangiopathy associated with lupus nephritis","volume":"2","author":"Park","year":"2018","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.semarthrit.2018.11.005_bib0056","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/rheumatology\/kev371","article-title":"A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor","volume":"55","author":"Wig","year":"2016","journal-title":"Rheumatol (Oxford)"},{"issue":"3","key":"10.1016\/j.semarthrit.2018.11.005_bib0057","doi-asserted-by":"crossref","first-page":"6625","DOI":"10.4081\/hr.2016.6625","article-title":"Atypical hemolytic uremic syndrome secondary to lupus nephritis, Responsive to Eculizumab","volume":"8","author":"Raufi","year":"2016","journal-title":"Hematol Rep"},{"issue":"6","key":"10.1016\/j.semarthrit.2018.11.005_bib0058","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/RHU.0000000000000290","article-title":"Eculizumab induces sustained remission in a patient with refractory primary catastrophic antiphospholipid syndrome","volume":"21","author":"Zikos","year":"2015","journal-title":"J Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2018.11.005_bib0059","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/ajt.12540","article-title":"Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation","volume":"14","author":"Lonze","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.semarthrit.2018.11.005_bib0060","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1056\/NEJMc0910965","article-title":"Eculizumab and renal transplantation in a patient with CAPS","volume":"362","author":"Lonze","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2018.11.005_bib0061","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1097\/TP.0000000000000267","article-title":"A case of thrombotic microangiopathy associated with antiphospholipid antibody syndrome successfully treated with eculizumab","volume":"98","author":"Bakhtar","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.semarthrit.2018.11.005_bib0062","article-title":"36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature","volume":"2014","author":"Strakhan","year":"2014","journal-title":"Case Rep Hematol"},{"issue":"26","key":"10.1016\/j.semarthrit.2018.11.005_bib0063","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1097\/MD.0000000000000143","article-title":"Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report","volume":"93","author":"Kronbichler","year":"2014","journal-title":"Med (Baltimore)"},{"issue":"8","key":"10.1016\/j.semarthrit.2018.11.005_bib0064","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1111\/ajt.12319","article-title":"Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes","volume":"13","author":"Canaud","year":"2013","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.semarthrit.2018.11.005_bib0065","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/art.34440","article-title":"Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab","volume":"64","author":"Shapira","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.semarthrit.2018.11.005_bib0066","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1111\/j.1600-6143.2011.03696.x","article-title":"Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation","volume":"11","author":"Hadaya","year":"2011","journal-title":"Am J Transplant"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017218304931?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017218304931?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T08:41:31Z","timestamp":1775292091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017218304931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0049017218304931"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2018.11.005","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2018.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}